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Abstract
Systemic corticosteroids are often considered the treatment of choice in the management of severe 
drug-induced hypersensitivity syndrome (DIHS), also known as drug reaction with eosinophilia 
and systemic symptoms (DRESS) syndrome. However, in instances when systemic steroids are 
contraindicated, when there is an inadequate response to steroids, or when a prolonged course of 
steroids is not ideal, alternate therapies may be considered. Cyclosporine has been reported as a 
successful alternative immunosuppressive therapy; however, only a few cases have been reported 
in the literature. This observational case report presents an instance where cyclosporine was 
successfully used to treat DRESS syndrome in a patient where systemic steroids were ineffective.
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Report of a Case
A 59-year-old man with a history of multiple myeloma was admitted to the hospital for a 
rash and new onset edema of the hands and face approximately five weeks after starting 
induction chemotherapy and antibiotic prophylaxis with trimethoprim/sulfamethoxazole 
(TMP/SMX). The patient developed numerous, coalescing, purpuric macules and papules, 
which covered most of his body (Figures 1a and 1b). The patient also had significant edema 
of the face and hands. The patient’s labs were notable for marked leukocytosis with 
hypereosinophilia and transaminitis with an alanine aminotransferase (ALT) of 212 and an 
aspartate aminotransferase (AST) of 54. A punch biopsy taken from one of the lesions and 
was most consistent with a purpuric drug eruption. A clinical diagnosis of DRESS syndrome 
was made, his TMP/SMX was discontinued, and he was started on prednisone, 1mg/kg/day. 
Despite these interventions, the patient’s hepatic enzymes continued to rise and peaked with 
an ALT of 1,765 and an AST of 1,337. The decision was made to start cyclosporine 5 
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mg/kg/day for a seven-day course, which resulted in rapid clinical and laboratory 
improvement (Figures 2a and 2b). The patient’s hepatic enzymes continued to trend down 
and normalized in approximately three weeks.
Discussion
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, also known as 
drug-induced hypersensitivity syndrome (DIHS), is fatal in approximately 10% of cases, 
most commonly due to hepatic necrosis1. Diagnosis of DRESS relies on recognition of the 
syndromes’ clinical symptoms (edema, rash, lymphadenopathy, fever) and signs of 
hematologic or internal organ involvement in the laboratory data2. Management of DRESS 
includes withdrawal of the suspected causative agent and supportive care 2. In cases of 
internal organ involvement, patients are also frequently prescribed a systemic 
immunosuppressant, most commonly corticosteroids1. Instances when systemic steroids are 
contraindicated, when there is inadequate response to steroids, or when a prolonged course 
of steroids is not ideal, alternate therapies may be considered. Review of the literature 
revealed seven other cases demonstrating the use of cyclosporine for the management of 
DRESS syndrome (see Table 1). In two of these cases, cyclosporine was effective as a first-
line agent 3; in three others, it was used successfully as a second-line therapy after failed 
initial management with steroids 1, 2, 4. Finally, in two other cases, systemic corticosteroids 
followed by cyclosporine both failed to resolve refractory DRESS syndrome 5, 6. This 
observational case report presents another instance where cyclosporine was successfully 
used in the management of DRESS syndrome and supplies further evidence that 
cyclosporine may provide an effective alternative or compliment to systemic corticosteroid 
therapy.
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Figures 1a and 1b. 
Purpuric eruption on abdomen and right leg of patient following initiation of induction 
chemotherapy and antibiotic prophylaxis with TMP/SMX.
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Figures 2a and 2b. 
Appearance of rash three days after initiating cyclosporine.
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Table 1.
Case reports of cyclosporine use in the management of DRESS.
Publication Year Causative Drug Initial Corticosteroid Therapy Cyclosporine Dosage Indication for Cyclosporine Result
20034 Phenytoin Prednisolone, 40 mg/day, 
followed by topical clobetosol 
proprionate, 0.05%, for a total 
of 200 mg weekly
4 mg/kg for 
approximately 6 
months
Steroid-resistant DRESS and 
iatrogenic Cushing’s 
syndrome
Full resolution; 
stable 9 months 
later
20051 Vancomycin Methylprednisolone, 100 mg 
IV, four times daily, followed 
by tapered dose of prednisone 
for several weeks
100 mg, twice daily, 
for 5 days
No improvement with 
corticosteroid therapy
Full resolution; 
stable 20 months 
later
20085 Celecoxib and ethambutol Methylprednisolone, 1,000 mg 
IV daily, followed by 75 mg 
prednisone daily
Patient suffered relapse 1 week 
later and was started on 
Methylprednisolone, 1,000 mg 
IV daily for another 3 days
Cyclosporine, 100 mg 
daily, with 60 mg 
methylprednisolone 
daily
Relapse Patient continued to 
decline despite 
initiation of 
cyclosporine and 
methylprednisolone. 
Patient was 
intubated and 
managed with 
intravenous 
immunoglobulin 
infusion (1 g/kg/
day) for 2 days. 
Patient eventually 
recovered following 
prolonged steroid 
taper.
20126 Sulfasalazine Patient initially managed with co-administration of high-dose dexamethasone with 
cyclosporine, followed by an unknown tapered dose of prednisone
No resolution; 
patient’s condition 
continued to 
deteriorate, and she 
eventually died of 
myocarditis 
approximately 6 
weeks after her 
initiation of 
sulfasalazine
20163 Carbamazepine Cyclosporine monotherapy with 100 mg twice daily for 7 days Full resolution of 
symptoms
20163 Minocycline Cyclosporine monotherapy with 5 mg/kg/day for 3 days Full resolution of 
symptoms
20172 Mexiletine 100 mg/day prednisolone for 9 
days, then 70 mg/day for 6 
days, followed-by self-wean by 
patient
5 mg/kg/day for 7 
days, followed by 100 
mg twice daily for 14 
days and then 150 mg 
daily for 20 days
Relapse of DRESS and 
development of steroid-
induced diabetes mellitus
Full resolution; 
stable 6 months 
later
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